KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Sales and Divestitures: 2011-2024

Historic Gains from Sales and Divestitures for Sarepta Therapeutics (SRPT) over the last 13 years, with Dec 2024 value amounting to $734,922.

  • Sarepta Therapeutics' Gains from Sales and Divestitures fell 60.96% to $38,050 in Q3 2025 from the same period last year, while for Sep 2025 it was $38,050, marking a year-over-year decrease of 60.96%. This contributed to the annual value of $734,922 for FY2024, which is 14.01% up from last year.
  • As of FY2024, Sarepta Therapeutics' Gains from Sales and Divestitures stood at $734,922, which was up 14.01% from $644,614 recorded in FY2023.
  • In the past 5 years, Sarepta Therapeutics' Gains from Sales and Divestitures ranged from a high of $734,922 in FY2024 and a low of $162,970 during FY2020.
  • Its 3-year average for Gains from Sales and Divestitures is $589,766, with a median of $644,614 in 2023.
  • Data for Sarepta Therapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 69.96% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Gains from Sales and Divestitures stood at $162,970 in 2020, then surged by 69.96% to $276,980 in 2021, then skyrocketed by 40.72% to $389,761 in 2022, then soared by 65.39% to $644,614 in 2023, then rose by 14.01% to $734,922 in 2024.